Erythema Severity Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 [clinicaltrials_resource:9c76a5b7dbbfbb9186b45623cb9a6e2d]
Measured by percent improvement on a scale of 0-4. Subjects received a 0 for no improvement, 1 for less than twenty-five percent improvement, a 2 for twenty-five to fifty percent improvement, a 3 for fifty to seventy-five percent improvement and a 4 for greater than seventy-five percent improvement. Mean scores from all continuing 16 participants were averaged for each encounter, for a total of 8 visits. The percent improvement in mean erythema severity was calculated by comparing the change in mean scores at week 48 to mean scores assessed at baseline.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Erythema Severity Baseline, Weeks 1, 4, 8, 12, 24, 36, 48 [clinicaltrials_resource:9c76a5b7dbbfbb9186b45623cb9a6e2d]
Measured by percent improvement on a scale of 0-4. Subjects received a 0 for no improvement, 1 for less than twenty-five percent improvement, a 2 for twenty-five to fifty percent improvement, a 3 for fifty to seventy-five percent improvement and a 4 for greater than seventy-five percent improvement. Mean scores from all continuing 16 participants were averaged for each encounter, for a total of 8 visits. The percent improvement in mean erythema severity was calculated by comparing the change in mean scores at week 48 to mean scores assessed at baseline.
Bio2RDF identifier
9c76a5b7dbbfbb9186b45623cb9a6e2d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9c76a5b7dbbfbb9186b45623cb9a6e2d
measure [clinicaltrials_vocabulary:measure]
Erythema Severity
time frame [clinicaltrials_vocabulary:time-frame]
Baseline, Weeks 1, 4, 8, 12, 24, 36, 48
description
Measured by percent improvemen ...... n scores assessed at baseline.
identifier
clinicaltrials_resource:9c76a5b7dbbfbb9186b45623cb9a6e2d
title
Erythema Severity Baseline, Weeks 1, 4, 8, 12, 24, 36, 48
@en
type
label
Erythema Severity Baseline, We ...... 6a5b7dbbfbb9186b45623cb9a6e2d]
@en